Suramin for the Treatment of Autism Trial (STAT): A Randomized, Double Blind, Crossover Trial of KZ101 in a Male Pediatric Population With Autism Spectrum Disorder
Children's Hospital of Orange County
Summary
Suramin has been found to correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic and environmental mouse models of autism. A preliminary clinical trial (SAT-1) examined the safety and activity of a single low-dose of suramin in children with ASD and concluded suramin showed promise as a novel approach to treatment of ASD. The current study, STAT-2A, will be a randomized, double-blind, crossover, 30-week study to evaluate the preliminary proof of concept, safety, and PK of suramin sodium (KZ101) with repeat dosing by IV infusion in males 5-14 years of age who have been diagnosed with ASD. The study will be conducted at approximately 3 sites contributing approximately 15 subjects per site. Total enrollment of approximately 45 subjects is planned to achieve approximately 36 participants completing the study.
Description
After up to a 4-week screening period, participants will undergo 8 weeks of active or placebo treatment (Period 1), followed by an 8-week washout period, and then cross over to 8 weeks of placebo or active treatment (Period 2). Patients will be followed for 2 weeks after completion of Period 2. Two dosing groups are designated as Group A, who are randomly assigned to active treatment with KZ101 in Period 1 and saline in Period 2, and Group B, who are randomly assigned to saline infusion in Period 1 and active treatment with KZ101 in Period 2. Dosing in both periods will consist of 2 IV infusio…
Eligibility
- Age range
- 5–14 years
- Sex
- Male
- Healthy volunteers
- No
Inclusion Criteria: \- Subject must meet all of the following criteria to be enrolled in this study. 1. Male, aged 5-14 years 2. Clinical diagnosis of ASD by DSM-5 criteria 3. ADOS-2 ≥ 7 on the comparison score for Modules 2-4 (completed within the last 2 years). 4. CGI-S ≥ 4 for socialization specific symptoms of ASD 5. Leiter-3 non-verbal IQ \> 70 6. Standard score \< 75 on the Socialization Domain of the Comprehensive Interview Form of the Vineland Adaptive Behavior Scale Third Edition 7. Subjects who are sexually active or potentially sexually active agree to use condoms with a spermicid…
Interventions
- DrugKZ101
For active treatment with KZ101, a loading dose of 454 mg/m2 (salt-free) will be followed by a treatment dose of 363 mg/m2 (salt-free).
- DrugPlacebo
Dosing in the placebo group will consist of a volume of normal saline equivalent to that given during the active treatment period for each participant.
Locations (3)
- Southwest Autism Research and Resource CenterPhoenix, Arizona
- Children's Hospital Orange County, Thompson Autism and Neurodevelopmental CenterOrange, California
- Kennedy Krieger InstituteBaltimore, Maryland